VALLEY COTTAGE, New York, August 7, 2017 /PRNewswire/ --
The global diabetic macular edema (DME) market is projectedto register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future Market Insights (FMI). The report estimates the market to reach US$ 3710.2 Mn in 2017; by 2027 this number is expected to
(Logo: http://photos.prnewswire.com/prnh/20161020/430874LOGO )
An Uptake of Intravitreal Implants by Patients to Drive Growth of the Market in North America
North America will remain dominant in the global diabetic macular edema market. An uptake of intravitreal implants by new as well as existing patients, who do not show any improvement post-treatment with intravitreal injections, is expected to sustain growth of the market in this region.
Although control of diabetes is a health priority in developed North American countries, such as the U.S., less attention is given to DME management, with diabetes-related caregivers tending to focus on treatment of diabetic complications. A major reason behind this is lack of effective treatment for DME in North America. In addition, an error exists between industry sponsored and independently run clinical trials. Most of the independent clinical trials for DME treatment lack long-term results pertaining to safety and efficacy of new combination therapies for DME. These factors are likely to inhibit growth of the market in North America.
Request a Sample Report with Table of Contents: http://www.futuremarketinsights.com/reports/sample/rep-gb-2697
Diabetic Macular Edema Market in Western Europe to Register the Highest CAGR through 2027
The diabetic macular edema market in Western Europe is expected to register a comparatively higher CAGR than other region segments through 2027. Pharmaceutical companies in this region are making substantial investments in research and development, new technologies, and infrastructure in order to capture a market share in the surging burden of eye diseases. This is expected to retain growth of the market in Western Europe.
However, patients in Western Europe resist the intake of intravitreal injections of anti-VEGF drugs, which leads to an instant increase in intraocular pressure causing severe pain in the head or eyes. This a major factor impeding growth of the diabetic macular edema market in Western Europe.
Preview Analysis on Global Diabetic Macular Edema Market Segmentation By Therapy Type - Anti-VEGF (Ranibizumab (Lucentis), Afilbercept (Eylea)),Corticosteroids (Fluocinolone Acetonide (Iluvien), Dexamethasone (Ozurdex)), Other Off-label Drugs (Triamcinolone, Acetonide, Bevacizumab and Pegaptanib); By Product Form - Intravitreal Injections, Intravitreal Implants; By Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Others: http://www.futuremarketinsights.com/reports/diabetic-macular-edema-market
Anti-VEGF will Remain Preferred Product in the Global Diabetic Macular Edema Market
Anti-VEGF will remain preferred product in the market, with sales estimated to expand at 1% CAGR through 2027. Eylea will continue to be the most lucrative anti-VEGF drug in the market. However, demand for corticosteroids will remain comparatively lower than anti-VEGF during the forecast period.
By product form, intravitreal injections will continue to be sought-after in the market, with sales poised to surpass US$ 4,000 Mn by 2027-end. Sales of intravitreal implants will register a comparatively higher CAGR than intravitreal injections through 2027.
Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: http://www.futuremarketinsights.com/askus/rep-gb-2697
Hospital pharmacy is estimated to remain the largest distribution channel in the market, as majority of countries across the globe dispense intravitreal injections and implants to outpatients by hospital pharmacies. Retail pharmacy, which mainly provides aliquots of off-label indications such as Avastin prescription, will register a comparatively low CAGR than hospital pharmacy in the market through 2027.
Key market players identified in FMI's report include Novartis AG, Bayer AG, Allergan Plc., F. Hoffman-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
More from FMI's Cutting-edge Intelligence:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Browse More Healthcare, Pharmaceuticals and Medical devices Market Insights
Contact Us 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 F: +1-845-579-5705 T (UK): +44(0)20-7692-8790 Sales: email@example.com Press Office: Press@futuremrketinsights.com
FMI Blog: http://www.fmiblog.com/
SOURCE Future Market Insights
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All